ADMA FY2025 SEC EDGAR DEF 14A #35 of 168 in industry

Adma Biologics, Inc. CEO pay ratio

The CEO earned $10.2M in FY2025 against median worker pay of $85,586 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-15
Industry
Chemicals & Pharmaceuticals
Industry rank
#35/168

Data updated August 2026

Subscribe to Adma Biologics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
120:1
Moderate (Scale: 0–1000:1)
CEO pay
$10.2M
Median worker
$85,586

Answer first

Adma Biologics, Inc.'s FY2025 CEO total of $10.2M ranks #516 of 1,423 complete filings; its 120:1 pay ratio ranks #545. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $85,586. Industry placement uses the FY2025 SIC-28 peer cohort (# 35 of 168, 80th percentile - top quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#516
$10.2M of 1,423 FY2025
Ratio rank
#545
120:1 of 1,423
Industry pct
80th
top quartile of industry peers by pay ratio

How Adma Biologics, Inc. ranks nationally

Adma Biologics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$10,237,326 Top 36% higher than 64% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). This entry sits in this band. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Adma Biologics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($10.2M) against pay ratio (120:1) for Adma Biologics, Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both7637807.59077309.010516810.511956312.013395813.637.8:161.1:184.5:1107.9:1131.3:1CEO total payPay ratio (CEO : median worker)Adma Biologics, Inc., CEO total pay: 10237326 · Pay ratio (CEO : median worker): 120:1Adma Biologics, Inc.Tronox Holdings plc, CEO total pay: 8235381 · Pay ratio (CEO : median worker): 121:1Tronox Holdings plcAni Pharmaceuticals Inc, CEO total pay: 10254756 · Pay ratio (CEO : median worker): 114:1Ani Pharmaceuticals IncPerimeter Solutions, Inc., CEO total pay: 8062080 · Pay ratio (CEO : median worker): 114:1Perimeter Solutions, Inc.Ingevity Corp, CEO total pay: 13134086 · Pay ratio (CEO : median worker): 127:1Ingevity Corp
Adma Biologics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Adma Biologics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Adma Biologics, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
120:1
FY2025
vs prior FY
+21:1
from FY2024 99:1
CEO $ YoY
+29%
$10.2M latest
Filings shown
2
FY2024–2025
Adma Biologics, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $7.9M - $80,331 99:1 -
2025 $10.2M +29% $85,586 120:1 +21:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1368514, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
120:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$10.2M
Companies in Industry
168
vs. Industry Median
Above
#35 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Adma Biologics, Inc.: MID · HEAVY pay ratio

Adma Biologics, Inc.'s FY2025 ratio 120:1 ranks #35 of 168 Chemicals & Pharmaceuticals filers (80th percentile). the CEO earned 120× the median employee ($85,586) in FY2025.

Median employee $85,586 (HIGH-MED); MID · HEAVY stamps put about 120 median-wage years per CEO year.

CEO Total Pay

$10.2M

FY2025 Summary Compensation, above median

Pay Ratio

120:1

Near industry median

Adma Biologics, Inc. in the higher Chemicals & Pharmaceuticals third

Adma Biologics, Inc.'s FY2025 ratio 120:1 ranks #35 of 168 Chemicals & Pharmaceuticals filers (80th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Adma Biologics, Inc.'s $10.2M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #516 and ratio rank #545 split - treat 120:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$10.2M
Median Employee Pay
$85,586
Pay Ratio
120:1
Filing Date
2026-04-15

Company Info

Ticker
ADMA
CIK
1368514
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1368514, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Adma Biologics, Inc.'s FY2025 ratio 120:1 ranks #35 of 168 Chemicals & Pharmaceuticals filers (80th percentile).

Read with Adma Biologics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MID · HEAVY · HIGH-MED.

Aptargroup, Inc. · HEAVY

ABS(ceo_total_comp) peer at $10.2M (Δ $6K lighter vs Adma Biologics, Inc.); STEEP · PAR-MED vs this page's MID · HEAVY · HIGH-MED.
First Citizens Bancshares Inc /de/ · HEAVY

ABS(ceo_total_comp) peer at $10.2M (Δ $10K heavier vs Adma Biologics, Inc.); MID · ELITE-MED vs this page's MID · HEAVY · HIGH-MED.
AdaptHealth Corp. · HEAVY

ABS(ceo_total_comp) peer at $10.2M (Δ $12K heavier vs Adma Biologics, Inc.); STEEP · PAR-MED vs this page's MID · HEAVY · HIGH-MED.
Fti Consulting, Inc · HEAVY

ABS(ceo_total_comp) peer at $10.2M (Δ $14K lighter vs Adma Biologics, Inc.); MODEST · ELITE-MED vs this page's MID · HEAVY · HIGH-MED.
Tronox Holdings plc (SIC 28 pole)

Tronox Holdings plc stamps MID · HEAVY nearest in-SIC by ABS(pay_ratio) to Adma Biologics, Inc.'s MID filing.
National dual ranks · #516/#545

Adma Biologics, Inc.'s FY2025 package sits #516 by CEO dollars and #545 by ratio under HEAVY · MID.
Comp structure · HEAVY

Adma Biologics, Inc.'s HEAVY CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Adma Biologics, Inc. (CIK 1368514), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.